Pharmacology and Toxicology

David Z. Cherney MDCM, PhD, FRCP(C)
Clinician Scientist, Division of Nephrology, University Health Network
Associate Professor
David Cherney MD, PhD
Contact Info
T: (416) 340-4151
F: (416) 340-4999
Location
Toronto General Hospital
585 University Ave, 8N-845
Toronto, ON, M5G 2N2
Appointments
Department of Medicine, University of Toronto
Department of Pharmacology & Toxicology, University of Toronto
Research Interests
physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation

Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Associate Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He receives operating funding from the Canadian Institutes of Health Research, JDRF the Heart and Stroke Richard Lewar Centre of Excellence and the Banting and Best Diabetes Center. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation. His research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and related cardiovascular disease.

Publications and Awards

View PubMed search of this faculty member's recent publications.

Recent Publications

  1. David Cherney, Patrick Lawler, Robert Rosenson. Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: An Emerging Role for Evolocumab? JACC 2019 (in press)
     
  2. Daniel Scarr, Leif E. Lovblom, Petter Bjornstad, Julie A. Lovshin, Yuliya Lytvyn, Mohammed A. Farooqi, Genevieve Boulet, Andrej Orszag, Vesta Lai, Alanna Weisman, Hillary A. Keenan, Michael H. Brent, Narinder Paul, Vera Bril, David Z.I. Cherney*, Bruce A. Perkins*. Estimating Glomerular Filtration Rate by Serum Creatinine Lacks Precision and Accuracy in Older Adults: Results from the Canadian Study of Longevity in Type 1 Diabetes. Kidney International - Reports (*co-senior authors) 2019 (in press)
     
  3. Kevin D. Burns, David Cherney. Renal Angiotensinogen and SGLT2 Inhibition: Insights into Experimental Diabetic Kidney Disease. American Journal of Nephrology (in press)
     
  4. Kengo Kidokoro*, David Cherney*, Hajime Nagasu, Minoru Satoh, Naoki Kashihara. Evaluation of alterations in glomerular hemodynamic function with SGLT2 inhibition and adenosine antagonism using in vivo imaging techniques. Circulation 2019 * co-first authors (in press)
     
  5. J.A. Lovshin, David Z. Cherney. Salt transport in diabetes: are there 2 sides to the coin? Nature Reviews Nephrology 2019 (in press)
     
  6. David Z.I. Cherney, Tony K.T. Lam. Metformin targets the gut to lower glucose levels in rats, mice, and humans. Cell Metabolism 2018 (in press)
     
  7. Julie Lovshin2, Bjornstad P, Daniel Scarr1, Leif E. Lovblom1, Mohammed A. Farooqi1, Genevieve Boulet1, Andrej Orszag1, Alanna Weisman1, Vesta Lai, Josephine Tse, Leslie Cham, Yuliya Lytvyn2, Mylan Ngo6, Hillary A. Keenan3, Michael H. Brent4, Narinder Paul5, Vera Bril6, Bruce A. Perkins, Cherney D. Atherosclerosis and microvascular complications: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care 2018 (in press). Senior Responsible Author
     
  8. David León Jiménez*, David Z. Cherney*, Petter Bjornstad, MD, Luis Castilla Guerra José Pablo Miramontes González. The Impact of Antihyperglycemic Agents as Novel Natriuretic Therapies in Diabetic Kidney Disease. AJP-Renal 2018 (in press).*Co-primary author
     
  9. Tony Lam, David Z. Cherney. Beta-cell protection and Type 1 Diabetes. Nature Medicine 2018;24(8):1089-90. Senior Responsible Author
     
  10. Daniel H. van Raalte, David Z. Cherney. Sodium glucose cotransporter (SGLT)-2 inhibition and Renal Ischemia: Potential Implications for Future Clinical Trials. Kidney International 2018;94(3):459-62. Senior Responsible Author
     
  11. Petter Bjornstad1, Lori Laffel2, William Tamborlane3, Gudrun Simons4, Stefan Hantel4, Max von Eynatten5, Jyothis George5, Jan Marquard5 David Z. Cherney6*. The Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth with Type 2 Diabetes. Diabetes Care 2018;41(8):e-129-30. Senior Responsible Author
     
  12. *Nancy Cardinez1, Leif E. Lovblom1, Johnny-Wei Bai1, Evan Lewis1, Daniel Scarr1, Julie Lovshin1, Yuliya Lytvyn6, Genevieve Boulet1, Mohammed A. Farooqi1, Andrej Orszag, Alanna Weisman1, Hillary A. Keenan2, Michael H. Brent3, Narinder Paul4, Vera Bril5, David Z. Cherney6*, Bruce A. Perkins1*. Sex differences in neuropathy and neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and its Complications 2018;32(7):660-4. *Co-Senior Responsible Author